ArticleScientific reports2026
Therapeutic effects and potential targets of UC-MSC-Exo in a mouse model of COPD.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research investigated the therapeutic efficacy and potential targets of exosomes derived from umbilical cord mesenchymal stem cells (UC-MSC-Exo) in the context of chronic obstructive pulmonary disease (COPD). UC-MSC-Exo were isolated from the culture supernatant. A model of COPD was induced through exposure to cigarette smoke (CS) and airway lipopolysaccharide (LPS) instillation. Mice in the UC-MSC-Exo group received 100 µg of exosomes via tail vein injection. Lung function, computed tomography imaging of the lungs, bronchoalveolar lavage fluid cell count, plasma levels of inflammatory factors, as well as histological assessments using hematoxylin and eosin staining and Masson’s trichrome staining of lung tissue were employed to assess the therapeutic efficacy. Single-cell transcriptome sequencing was utilized to investigate the potential targets of UC-MSC-Exo in improving lung function and exerting anti-inflammatory effects in COPD mouse models. The UC-MSC-Exo group exhibited significant enhancements in pulmonary function parameters, attenuation of lung CT abnormalities, reduced BALF cell counts, and decreased levels of plasma inflammatory markers. Histological analysis confirmed decreased inflammatory infiltration and collagen deposition. Single-cell sequencing analysis suggested that UC-MSC-Exo might modulate CXCR4 expression, suppress inflammation, and facilitate lung regeneration by modulating macrophage functionality. This investigation introduces novel therapeutic avenues and potential targets for managing COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.